Literatur
- 1
Ho S, Lau W Y, Leung T W, Johnson P J.
Internal radiation therapy for patients with primary or metastatic hepatic cancer:
a review.
Cancer.
1998;
83
1894-1907
- 2
Press O W.
Radiolabeled antibody therapy of B-cell lymphomas.
Semin Oncol.
1999;
26(Suppl 14)
58-65
- 3
Wahl R L, Zasadny K R, MacFarlane D, Francis I R, Ross C W, Estes J, Fisher S, Regan D,
Kroll S, Kaminski M S.
Iodine-131 anti-131 antibody for B-cell lymphoma: an update on the Michigan Phase
1 experience.
J Nucl Med.
1998;
39(Suppl)
S21-S27
- 4
Vose J M.
Anti body-targeted therapy for low-grade lymphoma. 1999,-36(Suppi 6):15-20.
Semin Hematol.
1999;
36(Suppl 6)
15-20
- 5
Wiseman G A, White C A, Witzig T E, Gordon L I, Emmanouilides C, Raubitschek A, Janakiraman N,
Gutheil J, Schilder R J, Spies S, Silverman D H, Grillo-Lopez A J.
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled
anti-CD20 monoclonal antibody.
Clin Cancer Res.
1999;
5(Suppl)
S3281-S3286
- 6
McDevitt M R, Finn R D, Ma D, Larson S M, Scheinberg D A.
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
J Nucl Med.
1999;
40
1722-1727
- 7
Sgouros G, Ballangrud A M, Jurcic J G, McDevitt M R, Humm J L, Erdi Y E, Mehta B M,
Finn R D, Larson S M, Scheinberg D A.
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195
(anti-CD33) in patients with leukemia.
J Nucl Med.
1999;
40
1935-1946
- 8
Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini A M, Giuliani G,
Casi M, Gentile R, Jekunen A A, Kairemo K J.
131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade
malignant glioma - phase I and II study.
Acta Oncol.
1999;
38
351-359
- 9
Akabani G, Reist C J, Cokgor I, Friedman A H, Friedman H S, Coleman R E, Zhao X G,
Bigner D D, Zalutsky M R.
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created
resection cavities in patients with malignant brain tumors.
J Nucl Med.
1999;
40
631-638
- 10
Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, Casi M, Sarti G,
Guiducci G, Giorgetti G, Gentile R, Santimaria M, Jermann E, Maecke H R.
Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal
antibodies labeled with 90Y: a phase I study.
Clin Cancer Res.
1999;
5(Suppl)
S3275-S3280
- 11
Larsen R H, Akabani G, Welsh P, Zalutsky M R.
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies
in human glioma and melanoma cells in vitro.
Radiat Res.
1998;
149
155-162
- 12
Riva P, Tison V, Arista A, Sturiale C, Franceschi G, Riva N, Casi M, Moscatelli G,
Campori F, Spinelli A.
Radioimmunotherapy of gastrointestinal cancer and glioblastomas.
Int J Biol Markers.
1993;
8
192-197
- 13
Behr T M, Salib A L, Liersch T, Behe M, Angerstein C, Blumenthal R D, Fayyazi A, Sharkey R M,
Ringe B, Becker H, Wormann B, Hiddemann W, Goldenberg D M, Becker W.
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the
liver: preclinical evaluation in comparison to standard chemotherapy and initial results
of a phase I clinical study.
Clin Cancer Res.
1999;
5(Suppl)
S3232-S3242
- 14
van Gog F B, Visser G W, Stroomer J W, Roos J C, Snow G B, van Dongen G A.
High dose rhenium-186-labeling of monoclonal antibodies for clinical application:
pitfalls and solutions.
Cancer.
1997;
80(Suppl)
S2360-S2370
- 15
Nakamoto Y, Sakahara H, Saga T, Sato N, Misaki T, Kosugi S, Konishi J.
Establishment and characterization of a breast cancer cell line stably expressing
sodium iodide symporters for novel cancer treatment:.
Eur J Nucl Med.
1999;
26
979
Prof. Dr. med. Klaus Hahn
Klinik und Poliklinik für Nuklearmedizin
Klinikum der LMU, Innenstadt
Ziemssenstr. 1
80336 München
Phone: Tel. 089/51602442
Fax: Fax 089/51604488
Email: E-mail: hahn@nuk.med.uni-muenchen.de
